ESMO abstracts are available

The following are the abstracts I was able to find. I suspect there are more.

RXDX abstract – 19 patients tested at different dose levels, 7 responded

https://www.webges.com/cslide/library/esmo/browse/search/88R#9f9C0382

Alectinib

Japanese trial, 28 pretreated with Crizotinib. Response rate was 58.3%

https://www.webges.com/cslide/library/esmo/browse/search/jZ#9f9v

Two novel mutations found to Alectinib.

https://www.webges.com/cslide/library/esmo/browse/search/aAA#9faD02W8

Ceritinib

Abstract 1295P

https://www.webges.com/cslide/library/esmo/browse/search/99N#9faC032R

Abstract 1293P

https://www.webges.com/cslide/library/esmo/browse/search/99Z#9faC03ff

AP26113

As of 17 March 2014, 125 pts were enrolled: 66 in Phase 1 and 59 in Phase 2. Among 51 evaluable ALK+ patients with prior crizotinib, 69% responded.

https://www.webges.com/cslide/library/esmo/browse/search/aAA#9faC02wJ

Crizotinib

https://www.webges.com/cslide/library/esmo/browse/search/7qT#679h02ct

https://www.webges.com/cslide/library/esmo/browse/search/7ig#7o3y0C4

https://www.webges.com/cslide/library/esmo/browse/search/aAA#9f9T035J

This entry was posted in alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, Brain metastases, crizotinib - Xalkori from Pfizer, Lung cancer, Potential Treatments, RXDX-101 - entrectinib - by Ignyta. Bookmark the permalink.

Leave a Reply